The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.

Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer (2015) 0.85

Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Support Care Cancer (2014) 0.85

Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol (2015) 0.82

Tumor suppression in basal keratinocytes via dual non-cell-autonomous functions of a Na,K-ATPase beta subunit. Elife (2016) 0.82

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. Acta Oncol (2015) 0.80

Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget (2016) 0.80

Prevalence of Hyponatremia in Palliative Care Patients. Indian J Palliat Care (2016) 0.79

Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS One (2016) 0.79

The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. BMC Res Notes (2016) 0.76

Kidney cancer: Low serum sodium linked to poor outcomes for patients with mRCC treated with targeted therapy. Nat Rev Urol (2013) 0.75

Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study. Support Care Cancer (2017) 0.75

Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention? Eur Urol (2013) 0.75

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 8.46

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16

Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 3.28

Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. Int J Urol (2012) 2.13

Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med (2007) 1.98

An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med (1995) 1.66

Hyponatremia in community-acquired pneumonia. Am J Nephrol (2007) 1.59

Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology (2008) 1.52

A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer (2000) 1.26

Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw (2006) 1.24

Cerebral salt-wasting syndrome: does it exist? Nephron (1999) 1.22

Clinical features and prognostic factors in childhood pneumococcal meningitis. J Microbiol Immunol Infect (2008) 1.17

Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care (2007) 1.13

Hyponatremia related to medical anticancer treatment. Support Care Cancer (1996) 1.13

Mild hyponatremia is associated with an increased risk of death in an ambulatory setting. Kidney Int (2013) 1.12

Use of admission serum lactate and sodium levels to predict mortality in necrotizing soft-tissue infections. Arch Surg (2007) 1.03

The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis (2008) 1.00

Recognition and treatment of hyponatremia in acutely ill hospitalized patients. Clin Ther (2007) 0.99

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer (2010) 0.98

Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res (2008) 0.96

Syndrome of inappropriate secretion of arginine vasopressin in patients with cancer of the head and neck. Ann Otol Rhinol Laryngol (1992) 0.95

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution. ISRN Oncol (2011) 0.87

The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer (2011) 0.86

Pathophysiology of ascites and functional renal failure in cirrhosis. J Hepatol (1988) 0.86

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 5.89

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol (2014) 5.10

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol (2015) 1.88

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol (2016) 1.67

Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2. Eur Urol (2014) 1.48

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol (2019) 1.38

Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol (2011) 1.06

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer (2013) 0.92

Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol (2016) 0.85

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs (2015) 0.81

Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. Clin Genitourin Cancer (2014) 0.79

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. Eur Urol (2014) 0.78

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol (2017) 0.77

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer (2014) 0.76

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother (2016) 0.75

Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med (2017) 0.75

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol (2020) 0.75

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer (2017) 0.75

Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis (2020) 0.75

Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clin Genitourin Cancer (2015) 0.75

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol (2016) 0.75

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Mol Cancer Ther (2016) 0.75